Trials / Completed
CompletedNCT06397001
Treatment of AA Amyloidosis
An Open-label Single Center, Single Patient Study of an Experimental Antisense Oligonucleotide (ASO) Treatment in AA Amyloidosis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Nelson Leung, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and efficacy of a subcutaneous injection of nL-SAA1-01in a patient with AA Amyloidosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nL-SAA1-01 | Personalized antisense oligonucleotide |
Timeline
- Start date
- 2023-11-28
- Primary completion
- 2024-12-02
- Completion
- 2024-12-02
- First posted
- 2024-05-02
- Last updated
- 2025-02-19
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06397001. Inclusion in this directory is not an endorsement.